Coagulation Reference Values and Indications for the Use of Plasma Derivatives in Neonates: A Narrative Review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.25754/pjp.2022.26058 |
Resumo: | Normal levels of coagulation factors in neonates are generally lower, which lead to prolonged clotting times, namely prothrombin time and activated partial thromboplastin time. These tests are frequently requested in neonatal intensive care units, and altered values are commonly found. However, these coagulation factor deficiencies are physiologic. Developmental hemostasis is a process that leads to the progressive increase of coagulation factor levels from birth to adulthood. It is crucial to define appropriate reference values for activated partial thromboplastin time, prothrombin time, and fibrinogen levels to avoid unnecessary transfusions. Physicians tend to prophylactically transfuse neonates in the presence of abnormal test results in an attempt to correct these deficiencies and decrease bleeding risk. As these changes are not associated with an increased risk of bleeding, namely intraventricular hemorrhage, most neonates do not require the transfusion of plasma products. In fact, transfusion of blood products has risks, and transfusion recipients should be carefully selected. This review aimed to determine the reference range values for fibrinogen and clotting times (prothrombin time and activated partial thromboplastin time) in neonates. Moreover, it was attempted to identify the specific indications for the transfusion of plasma derivatives. This review emphasizes the need for evidence-based reference ranges for coagulation tests (activated partial thromboplastin time, prothrombin time, fibrinogen), in preterm and full-term infants, as well as the importance of establishing universal guidelines for the transfusions of plasma products to ensure a standard clinical approach to this subject. |
id |
RCAP_893eda82ed742d1466e54e9d7c3d56ba |
---|---|
oai_identifier_str |
oai:ojs.revistas.rcaap.pt:article/26058 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Coagulation Reference Values and Indications for the Use of Plasma Derivatives in Neonates: A Narrative ReviewValores de referência de coagulação e indicações para o uso de derivados de plasma em recém-nascidos - uma revisãoReview articlesNormal levels of coagulation factors in neonates are generally lower, which lead to prolonged clotting times, namely prothrombin time and activated partial thromboplastin time. These tests are frequently requested in neonatal intensive care units, and altered values are commonly found. However, these coagulation factor deficiencies are physiologic. Developmental hemostasis is a process that leads to the progressive increase of coagulation factor levels from birth to adulthood. It is crucial to define appropriate reference values for activated partial thromboplastin time, prothrombin time, and fibrinogen levels to avoid unnecessary transfusions. Physicians tend to prophylactically transfuse neonates in the presence of abnormal test results in an attempt to correct these deficiencies and decrease bleeding risk. As these changes are not associated with an increased risk of bleeding, namely intraventricular hemorrhage, most neonates do not require the transfusion of plasma products. In fact, transfusion of blood products has risks, and transfusion recipients should be carefully selected. This review aimed to determine the reference range values for fibrinogen and clotting times (prothrombin time and activated partial thromboplastin time) in neonates. Moreover, it was attempted to identify the specific indications for the transfusion of plasma derivatives. This review emphasizes the need for evidence-based reference ranges for coagulation tests (activated partial thromboplastin time, prothrombin time, fibrinogen), in preterm and full-term infants, as well as the importance of establishing universal guidelines for the transfusions of plasma products to ensure a standard clinical approach to this subject.Sociedade Portuguesa de Pediatria2022-05-23info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttps://doi.org/10.25754/pjp.2022.26058eng2184-44532184-3333Todo Bom Costa, SaraPalaré, Maria JoãoMendes Graça, Andréinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-08-03T02:58:24Zoai:ojs.revistas.rcaap.pt:article/26058Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:25:40.284040Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Coagulation Reference Values and Indications for the Use of Plasma Derivatives in Neonates: A Narrative Review Valores de referência de coagulação e indicações para o uso de derivados de plasma em recém-nascidos - uma revisão |
title |
Coagulation Reference Values and Indications for the Use of Plasma Derivatives in Neonates: A Narrative Review |
spellingShingle |
Coagulation Reference Values and Indications for the Use of Plasma Derivatives in Neonates: A Narrative Review Todo Bom Costa, Sara Review articles |
title_short |
Coagulation Reference Values and Indications for the Use of Plasma Derivatives in Neonates: A Narrative Review |
title_full |
Coagulation Reference Values and Indications for the Use of Plasma Derivatives in Neonates: A Narrative Review |
title_fullStr |
Coagulation Reference Values and Indications for the Use of Plasma Derivatives in Neonates: A Narrative Review |
title_full_unstemmed |
Coagulation Reference Values and Indications for the Use of Plasma Derivatives in Neonates: A Narrative Review |
title_sort |
Coagulation Reference Values and Indications for the Use of Plasma Derivatives in Neonates: A Narrative Review |
author |
Todo Bom Costa, Sara |
author_facet |
Todo Bom Costa, Sara Palaré, Maria João Mendes Graça, André |
author_role |
author |
author2 |
Palaré, Maria João Mendes Graça, André |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Todo Bom Costa, Sara Palaré, Maria João Mendes Graça, André |
dc.subject.por.fl_str_mv |
Review articles |
topic |
Review articles |
description |
Normal levels of coagulation factors in neonates are generally lower, which lead to prolonged clotting times, namely prothrombin time and activated partial thromboplastin time. These tests are frequently requested in neonatal intensive care units, and altered values are commonly found. However, these coagulation factor deficiencies are physiologic. Developmental hemostasis is a process that leads to the progressive increase of coagulation factor levels from birth to adulthood. It is crucial to define appropriate reference values for activated partial thromboplastin time, prothrombin time, and fibrinogen levels to avoid unnecessary transfusions. Physicians tend to prophylactically transfuse neonates in the presence of abnormal test results in an attempt to correct these deficiencies and decrease bleeding risk. As these changes are not associated with an increased risk of bleeding, namely intraventricular hemorrhage, most neonates do not require the transfusion of plasma products. In fact, transfusion of blood products has risks, and transfusion recipients should be carefully selected. This review aimed to determine the reference range values for fibrinogen and clotting times (prothrombin time and activated partial thromboplastin time) in neonates. Moreover, it was attempted to identify the specific indications for the transfusion of plasma derivatives. This review emphasizes the need for evidence-based reference ranges for coagulation tests (activated partial thromboplastin time, prothrombin time, fibrinogen), in preterm and full-term infants, as well as the importance of establishing universal guidelines for the transfusions of plasma products to ensure a standard clinical approach to this subject. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-05-23 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.25754/pjp.2022.26058 |
url |
https://doi.org/10.25754/pjp.2022.26058 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
2184-4453 2184-3333 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Sociedade Portuguesa de Pediatria |
publisher.none.fl_str_mv |
Sociedade Portuguesa de Pediatria |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799133525837873153 |